Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by investment analysts at B. Riley in a report released on Friday, January 24th, TipRanks reports. They presently have a $83.00 target price on the biotechnology company’s stock. B. Riley’s target price suggests a potential upside of 98.04% from the company’s current price.
Several other brokerages have also recently commented on ARWR. S&P Equity Research reaffirmed a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 26th. Leerink Swann initiated coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, January 21st. They issued an “underperform” rating and a $32.00 target price for the company. Svb Leerink initiated coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, January 21st. They set an “underperform” rating and a $32.00 price objective for the company. Piper Jaffray Companies increased their price objective on Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, December 9th. Finally, BidaskClub lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 16th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $61.14.
ARWR opened at $41.91 on Friday. The stock has a market capitalization of $4.26 billion, a price-to-earnings ratio of 60.74 and a beta of 1.97. Arrowhead Pharmaceuticals has a 1-year low of $12.72 and a 1-year high of $73.72. The business has a 50 day moving average of $58.14 and a 200-day moving average of $42.94.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Monday, November 25th. The biotechnology company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.03). The firm had revenue of $43.29 million during the quarter, compared to the consensus estimate of $36.97 million. Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -0.15 EPS for the current fiscal year.
In other news, General Counsel Patrick O’brien sold 14,625 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $60.12, for a total value of $879,255.00. Following the completion of the sale, the general counsel now directly owns 267,406 shares in the company, valued at $16,076,448.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Christopher Richard Anzalone sold 37,967 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $69.15, for a total value of $2,625,418.05. Following the completion of the sale, the chief executive officer now owns 2,116,160 shares of the company’s stock, valued at $146,332,464. The disclosure for this sale can be found here. Insiders have sold 248,518 shares of company stock valued at $15,591,357 over the last quarter. Corporate insiders own 4.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its position in Arrowhead Pharmaceuticals by 96.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 500 shares during the period. Global Retirement Partners LLC acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $44,000. First Mercantile Trust Co. acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $101,000. Evoke Wealth LLC acquired a new stake in Arrowhead Pharmaceuticals in the third quarter worth about $116,000. Finally, NEXT Financial Group Inc acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $139,000. Hedge funds and other institutional investors own 69.81% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
See Also: Quantitative Easing
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
